We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+39.2%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$505M
Cap. Flow
+$114M
Cap. Flow %
7.17%
Top 10 Hldgs %
57.57%
Holding
93
New
29
Increased
21
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$33.8M
2
GILD icon
Gilead Sciences
GILD
+$30.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$26.9M
4
LLY icon
Eli Lilly
LLY
+$22.9M
5
ABBV icon
AbbVie
ABBV
+$17.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$27.6M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.6M
4
BIIB icon
Biogen
BIIB
+$16.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Miscellaneous 8.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$14.1M 0.89%
+252,958
New +$10.8M
TGTX icon
27
TG Therapeutics
TGTX
$8.37B
$13.6M 0.86%
696,390
+421,085
+153% +$6.78M
INSM icon
28
Insmed
INSM
$28.1B
$13.3M 0.84%
+483,967
New +$11.5M
PBYI icon
29
Puma Biotechnology
PBYI
$467M
$12.5M 0.79%
1,197,630
+559,604
+88% +$5.79M
NCNA
30
NuCana
NCNA
$5.7M
$12.3M 0.77%
453
– –
SUPN icon
31
Supernus Pharmaceuticals
SUPN
$2.45B
$11.4M 0.72%
+478,329
New +$10.6M
ZYME icon
32
Zymeworks
ZYME
$1.94B
$10.8M 0.68%
299,734
+249,745
+500% +$9.2M
MYOK
33
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$10.8M 0.68%
111,810
-63,308
-36% -$5.28M
MIRM icon
34
Mirum Pharmaceuticals
MIRM
$5.99B
$10.5M 0.66%
541,701
+123,112
+29% +$2.06M
OEF icon
35
PUT
iShares S&P 100 ETF
OEF
$20.3B
$10M 0.63%
+70,000
New +$9.42M
KURA icon
36
Kura Oncology
KURA
$1.08B
$9.96M 0.63%
+610,979
New +$8.81M
AKBA icon
37
Akebia Therapeutics
AKBA
$264M
$9.26M 0.58%
+681,892
New +$7.05M
CHMA
38
DELISTED
Chiasma, Inc. Common Stock
CHMA
$8.77M 0.55%
1,630,221
– –
KDMN
39
DELISTED
Kadmon Holdings, Inc.
KDMN
$7.84M 0.49%
1,530,864
+4,686
+0.3% +$21K
BMRN icon
40
BioMarin Pharmaceuticals
BMRN
$12.5B
$7.76M 0.49%
62,897
-177,149
-74% -$17.6M
QQQ icon
41
PUT
Invesco QQQ Trust
QQQ
$489B
$7.43M 0.47%
+30,000
New +$6.72M
BPMC
42
DELISTED
Blueprint Medicines
BPMC
$7.4M 0.47%
94,891
+31,791
+50% +$2.15M
AXSM icon
43
Axsome Therapeutics
AXSM
$11B
$7.16M 0.45%
86,978
+13,815
+19% +$1.06M
LQDA icon
44
Liquidia Corp
LQDA
$6.19B
$6.74M 0.42%
+800,000
New +$6.07M
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.25B
$6.47M 0.41%
1,357,848
+542,158
+66% +$2.17M
AGTC
46
DELISTED
Applied Genetic Technologies Corporation
AGTC
$6.34M 0.4%
1,145,254
+82,639
+8% +$378K
CNST
47
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.22M 0.39%
+207,087
New +$7.46M
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.21M 0.39%
241,908
+189,903
+365% +$3.84M
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
$5.98M 0.38%
1,651,411
+135,782
+9% +$353K
PTGX icon
50
Protagonist Therapeutics
PTGX
$9.39B
$5.76M 0.36%
+326,064
New +$4.09M
1
2
3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2020 Portfolio in Review

As of Q2 2020, Sofinnova Investments held 93 positions worth $1.59B, up 47% from $1.08B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments deployed $114M of net new capital in Q2 2020, opening 29 new positions and adding to 21 existing holdings. Its largest new stake was Akouos Inc: 1,515,073 shares worth $34.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $17.6M trimmed.

  • Sofinnova Investments's largest Q2 2020 buy was Akouos Inc: 1,515,073 shares worth $34.1M.
  • Sofinnova Investments added most to AbbVie in Q2 2020, an estimated $17.8M increase.
  • Sofinnova Investments's biggest Q2 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.6M.
  • Sofinnova Investments fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $27.6M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.59B portfolio in Q2 2020.
  • Sofinnova Investments opened 29 new positions and closed 17 in Q2 2020.
  • Sofinnova Investments's portfolio value rose 47% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.